Anthera Pharmaceuticals Inc. (ANTH) News Nov 12, 2014, 4:00

New Post Public Reply Private Reply Replies (0) Message Board

Nov 21, 2014 at 4:54 AM

Anthera Pharmaceuticals Inc. (ANTH) News Nov 12, 2014, 4:00 p.m.
MarketWatch News on ANTH
Stock futures edge up after retail, claims data 9:23 a.m. Dec. 12, 2013 - Victor Reklaitis
Stocks to watch Thursday: Libbey, J.M. Smucker 5:56 a.m. July 19, 2012 - MarketWatch
Anthera cut to sell by Citigroup 7:42 a.m. June 29, 2012 - Greg Morcroft
Thursday’s top gaining and declining stocks 3:54 p.m. June 28, 2012 - MarketWatch
Anthera plunges on drug study 9:36 a.m. June 28, 2012 - Val Brickates Kennedy
Stocks to watch Friday: UPS, AK Steel, AmeriGas 5:43 a.m. March 16, 2012 - MarketWatch
Monday’s biggest gaining and declining stocks 4:24 p.m. March 12, 2012 - Kate Gibson
Anthera plunges 50% on failed study 10:50 a.m. March 12, 2012 - Val Brickates Kennedy
U.S. stock futures fall before euro-area meeting 8:04 a.m. March 12, 2012 - Barbara Kollmeyer
Stocks to watch Monday: Coca-Cola, Michael Kors 5:45 a.m. March 12, 2012 - MarketWatch
Green Mountain slips, Anthera sinks after hours 6:47 p.m. March 9, 2012 - Carla Mozee
Anthera shares plunge 60% in after-hours trade 5:46 p.m. March 9, 2012 - Carla Mozee
Friday’s biggest gaining & declining stocks 3:36 p.m. Dec. 2, 2011 - Kate Gibson
Tuesday’s biggest gaining and declining stocks 2:08 p.m. May 17, 2011 - Greg Morcroft
Pernix leads drug stocks south 12:31 p.m. May 17, 2011 - Val Brickates Kennedy

Other News on ANTH
10-Q: ANTHERA PHARMACEUTICALS INC 4:57 p.m. Nov. 14, 2014 - Edgar Online - (EDG = 10Q, 10K)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns 9:16 a.m. Nov. 7, 2014 - Seeking Alpha
Qiagen's Molecular Diagnostics, Global Market Show Strength - Analyst Blog 1:50 p.m. Sept. 26, 2014 - Zacks.com
Genomic Health Upbeat on Strong International Performance - Analyst Blog 2:00 p.m. Sept. 25, 2014 - Zacks.com
Zacks Rank #1 Additions for Thursday - Tale of the Tape 8:30 a.m. Sept. 25, 2014 - Zacks.com
The 52-Week Low Club for Friday 2:58 p.m. Sept. 5, 2014 - 247WallSt.com
10-Q: ANTHERA PHARMACEUTICALS INC 12:06 p.m. Aug. 14, 2014 - Edgar Online - (EDG = 10Q, 10K)
Anthera (ANTH) Enters Oversold Territory - Tale of the Tape 9:41 a.m. Aug. 11, 2014 - Zacks.com
Anthera Pharmaceuticals (ANTH) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape 8:31 a.m. Aug. 4, 2014 - Zacks.com
Anthera Acquires Sollpura from Eli Lilly - Analyst Blog 4:20 p.m. July 18, 2014 - Zacks.com
Exelixis (EXEL) Soars: Stock Adds 23% in Session - Tale of the Tape 8:04 a.m. July 15, 2014 - Zacks.com
Anthera buys pancreatic therapy from Eli Lilly 4:31 p.m. July 14, 2014 - Seeking Alpha
Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events 8:30 a.m. July 14, 2014 - TheStreet.com
Fire Up The Immuno-Oncology Powerhouses: John McCamant 4:39 p.m. June 19, 2014 - Seeking Alpha
Anthera Pharmaceuticals (ANTH) Jumps: Stock Rises 10.3% - Tale of the Tape 7:51 a.m. May 16, 2014 - Zacks.com
10-Q: ANTHERA PHARMACEUTICALS INC 4:25 p.m. May 14, 2014 - Edgar Online - (EDG = 10Q, 10K)
10-K: ANTHERA PHARMACEUTICALS INC 4:22 p.m. March 28, 2014 - Edgar Online - (EDG = 10Q, 10K)
Anthera Pharmaceuticals: Recent Developments, Both Good And Bad 12:20 p.m. Oct. 31, 2013 - Seeking Alpha
A Promising Future For Anthera's Blisibimod 4:58 p.m. Sept. 27, 2013 - Seeking Alpha
BioLineRx Files for BL-7010 Study Initiation - Analyst Blog 4:25 p.m. Sept. 25, 2013 - Zacks.com

Press Releases on ANTH
Anthera and Patheon Sign Manufacturing Agreement for Liprotamase Phase III Registration Trial 11:00 a.m. Nov. 20, 2014 - PR Newswire - PRF
Anthera Pharmaceuticals Reports 2014 Third Quarter Financial Results and Operational Update 4:05 p.m. Nov. 14, 2014 - PR Newswire - PRF
Anthera Pharmaceuticals Announces Update on Strategic Partnership Discussions for Blisibimod 3:00 p.m. Oct. 1, 2014 - PR Newswire - PRF
Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 4:40 p.m. July 28, 2014 - PR Newswire - PRF
Anthera Pharmaceuticals Announces Acquisition of Sollpura® (liprotamase) for Exocrine Pancreatic Insufficiency From Eli Lilly and Company 3:42 p.m. July 14, 2014 - PR Newswire - PRF
Anthera Pharmaceuticals Appoints Brian R. Mueller to Board of Directors 4:00 p.m. June 23, 2014 - PR Newswire - PRF
Anthera Pharmaceuticals Appoints Dr. Philip Sager to Board of Directors 2:30 p.m. June 13, 2014 - PR Newswire - PRF
Top Gainers Technical Data -- Research on Zix, Textura, Recon Technology, and Anthera Pharma 9:46 a.m. May 16, 2014 - PR Newswire - PRF
Anthera Pharmaceuticals Reports 2014 First Quarter Financial Results and Operational Update 7:30 a.m. May 13, 2014 - PR Newswire - PRF
Anthera Pharmaceuticals Announces Personnel Changes 3:30 p.m. March 31, 2014 - PR Newswire - PRF
Anthera Pharmaceuticals Reports 2013 Fourth Quarter And Fiscal Year Financial Results and Operational Update 5:01 p.m. March 12, 2014 - PR Newswire - PRF
Hansen Medical Announces Appointment of Chris Lowe as Interim CEO; Bruce Barclay to Depart the Company 4:05 p.m. Feb. 10, 2014 - Marketwire
Anthera Pharmaceuticals to Present at Leerink Swann, Cowen & Co., and BIO CEO Healthcare Conferences 4:42 p.m. Jan. 30, 2014 - PR Newswire - PRF
FLG Partners Announces Chris Lowe as a New Partner 1:09 p.m. Jan. 28, 2014 - Marketwire
Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference 5:00 p.m. Nov. 27, 2013 - PR Newswire
Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update 3:30 p.m. Oct. 29, 2013 - PR Newswire
Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting 7:30 a.m. Sept. 25, 2013 - PR Newswire
Anthera Pharmaceuticals Reports 2013 Second Quarter Financial Results 4:14 p.m. July 30, 2013 - PR Newswire
Technical Briefing: Accuray, Antares Pharma, Chelsea Therapeutics, and Anthera Pharma 10:15 a.m. July 26, 2013 - PR Newswire
Anthera Pharmaceuticals Announces 1-for-8 Reverse Split of Stock 4:00 p.m. July 12, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

OTconnect on Apple Watch: A New Fitness Era Dawns

What’s Orangetheory Up To Now? Ah, fitness gadgets, where everyone’s seemingly got a scheme brewing. This time it's Orangetheory (OTF), turning your Apple Watch into your new best gym buddy. October 22, 2026, marks the launch of OTconnect for Apple Watch, offering a slick way for enthusiasts to tune into their own sweat metrics. If you’re already an Apple Watch...

2026 Merkin Prize Champions Cochlear Implant Innovators

Sometimes, the world flips its script. In 2026, five fearless innovators grabbed the spotlight at the Broad Institute. If you're not familiar with Graeme Clark, Erwin and Ingeborg Hochmair, Michael Merzenich, or Blake Wilson, well then, you've been snoozing under a rock. These folks were decorated with the prestigious Merkin Prize for crafting the modern cochlear...

Rentvine Unleashes AI Innovations in Property Management

Rentvine's Leap in AI Technology Right off the bat, let's give these guys some due credit. Rentvine, located in Bonita Springs, is tearing through the property management software scene like a train on rocket fuel. They just rolled out a suite of AI tools that's shaking up the single-family rentals management industry. During NARPM National in Las Vegas, they showcased...

Robotic Tiling Deal Boosts Foley Tile's National Reach

Robots Changing the Tiling Game Human Friendly Robotics (HFR) just dropped a game-changer—a $3.55 million deal with Foley Tile that's shaking up the tiling scene. For folks not glued to the market, this means HFR's Tyler robots are now neck-deep in Arizona soil, tasked with tiling jobs that once had the Foley crew running ragged. The Motherload of Opportunities Jerry...

NYC's Carriage Horse Ban: A New Era for Urban Welfare

You've got to hand it to New York City—this isn't just another Tuesday twist. The City Council's decision to nix horse-drawn carriages is like throwing a wrench in an antique machine. It's a bold move in a concrete jungle that's constantly wearing new coats. Tradition vs. Welfare: The Crux For years, the idea of horses prancing down NYC streets seemed like a quaint nod...

ASPR AI Unveils Private Sales Agent Studio

Pushing Sales AI Into a Secure Future Picture a world where your most sensitive sales data stays safely behind your own digital doors. ASPR AI is shaking up the game by launching its Private Sales Agent Studio, a move that catapults enterprise sales management into a new era of control and customization. Why Private Means Business Here's the meat of it: sales AI usually...

Seatrium, Karpowership Push Forward with Powership Deal

Seatrium Dives Deeper with Karpowership Here's a new chapter in the energy game, folks: Seatrium Limited and Karpowership are tightening their ties, sealing a deal to churn out these futuristic Whale Class Powerships. They're not just slapping some paint onto old relics; they're pioneering hydrogen-ready floating power plants that might just light up more than a few...

Visteon Reports Q3 2026 Results with Mixed Signals

Visteon's Q3 2026 Financial Performance: Insights and Implications You'd think by now that anything to do with supply chain hiccups wouldn’t surprise me, but Visteon Corporation’s recent third quarter results got my gears grinding yet again. Here's the scoop: Visteon pulled in $970 million in sales, strutting around with a 10% growth-over-market. Their resilience...

Elanco's Strategic Shift: Jamie Preston Takes the Helm

Elanco's Bold HR Transition: A New Leader Steps Up Well, here's a shake-up that might just turn a few heads in the corporate world. Elanco Animal Health, the outfit with the ticker NYSE:ELAN that many have their eyes on, is shuffling its HR deck, bringing in Jamie Preston from Eli Lilly to take charge as the new Chief People Officer. Mark November 3rd on your calendars;...

Carrier Drops $600M on U.S. Manufacturing Boost

A Mighty Move in Manufacturing Carrier Global Corporation's recent muscle-flexing is something rarer than a golden goose in today's market—a $600 million thrust into beefing up U.S. manufacturing and engineering. You can't help but wonder if this is overzealous optimism or a meticulously calculated power play. Clocks don't tick this loudly without good reason, of...